/ /

  • linkedin
  • Increase Font
  • Sharebar

    Stroke Prevention in the Patient with Afib and T2DM: NOACs vs VKAs


    In patients with atrial fibrillation (AF), comorbid type 2 diabetes (T2DM) is independently associated with a 2.5-3.0% increase in absolute stroke risk per year. T2DM also is an independent risk factor for both stroke and AF. Overlap in the pathophysiologies of these 2 important risk factors is not well understood nor do current practice guidelines provide evidence-based recommendations on optimal management of patients with both conditions.

    In an effort to advance understanding of how best to manage stroke risk in the setting of AF and T2DM, Plitt and colleagues analyzed data on patients taken from the clinical trials to determine the safey and effiicacy of tne novel oral anticoagulants. Specifically, they were interested to see the differential efficacy of NOACs vs warfarin in preventing thromboembolism in this dually affected group.

    Results are higlighted in the following slides.



    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available